← All stocks

Enliven Therapeutics, Inc.

ELVN Net selling
CIK 0001672619 #1481 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$76.51M
$9.19M on a plan · $15.34M straight out of an exercise
Sold at will
$51.98M
7 of 79 sales
Net
−$76.51M
−$51.98M against sales at will

By person

10 insiders · 81 transactions

There is no salary here to measure against. Enliven Therapeutics, Inc.'s chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
ORBIMED ADVISORS LLC entity
10% owner
$51.68M (6)
−$51.68M
6,555,102
8.95%
$389.02M
−14.8%
Derynck Mika K
Director
$9.56M (1) scheduled
−$9.56M
0
0.0000%
$0.00
Collins Helen Louise
CHIEF MEDICAL OFFICER
$5.14M (21) scheduled
−$5.14M
25,000
0.0341%
$1.48M
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER
$5.04M (15) scheduled
−$5.04M
758,938
1.04%
$45.04M
−29.6%
Patel Anish
CHIEF OPERATING OFFICER
$1.74M (7) scheduled
−$1.74M
235,011
0.3207%
$13.95M
−31.7%
Hohl Benjamin
CHIEF FINANCIAL OFFICER
$1.30M (12) scheduled
−$1.30M
40,036
0.0546%
$2.38M
Kunkel Lori Anne
Director
$850.25K (5) scheduled
−$850.25K
41,884
0.0572%
$2.49M
−8.8%
Kintz Samuel
PRESIDENT AND CEO
$785.43K (6) scheduled
−$785.43K
890,392
1.22%
$52.84M
−15.0%
Heyman Richard A.
Director
$413.38K (6) scheduled
−$413.38K
146,320
0.1997%
$8.68M
−13.4%
Ballal Rahul D.
Director
22,341
0.0305%
$1.33M
0.0%

Nothing of that kind in this period.

What was left out

Form 4 filings counted 55
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 41
Sales straight out of an exercise 31
Sales at will 7
Transactions with no price 0
Shares from compensation/vesting 441,843
History held since 16 Mar 2020